Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)

Bernstein, Jonathan A., M.D.

Status and phase: Unknown; Phase 4

Conditions: Rhinitis

Treatments: Drug: montelukast; Drug: placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00406094

NARES

Details and patient eligibility

About

The purpose of this trial is to determine if patients with NARES treated with montelukast (Singulair) will have improved nasal symptom scores and reduced nasal eosinophils.

Full description

Patients will receive either montelukast or placebo in the treatment of NARES. 4 visits will be conducted over 12 weeks. A history and physical will be performed at the beginning of the trial and at the end. Skin testing will be done at Visit 1. Nasal smears and lavages will be performed at every visit. Patients will be compensated for time and travel.

Enrollment: 6 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged 18 - 65 years
• Diagnosed with NARES

Exclusion criteria

• Smokers, exposed to passive smoke
• Diagnosis of seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), or vasomotor rhinitis (VMR)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

6 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

montelukast

Treatment:

Drug: montelukast

2

Placebo Comparator group

Description:

placebo

Treatment:

Drug: placebo